Scarica l'app Stockscreener
25.52
1.51%
0.38
Dopo l'orario di chiusura:
25.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews
Learn to Evaluate (APLS) using the Charts - Stock Traders Daily
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World
Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc. (APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low – What’s Next? - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus.com
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Apellis Pharmaceuticals CFO sells shares worth $93,953 - MSN
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Apellis Pharmaceuticals Reports Strong 2024 Growth - TipRanks
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Apellis Pharmaceuticals: Strong Buy Rating Maintained Amid Market Share Adjustments - TipRanks
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges - Investing.com Australia
Apellis Pharmaceuticals reports Q4 revenue beat, shares fall on Syfovre guidance - Investing.com Australia
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge - Investing.com
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Apellis Pharmaceuticals Shares Are in Flux - TipRanks
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss - Marketscreener.com
APELLIS PHARMACEUTICALS Earnings Results: $APLS Reports Quarterly Earnings - Nasdaq
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Revenue $212.5M, vs. FactSet Est of $198.8M - Marketscreener.com
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises -February 28, 2025 at 07:28 am EST - Marketscreener.com
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):